CA2101775C - Methode pour abaisser l'hyperglycemie chez l'homme - Google Patents

Methode pour abaisser l'hyperglycemie chez l'homme

Info

Publication number
CA2101775C
CA2101775C CA002101775A CA2101775A CA2101775C CA 2101775 C CA2101775 C CA 2101775C CA 002101775 A CA002101775 A CA 002101775A CA 2101775 A CA2101775 A CA 2101775A CA 2101775 C CA2101775 C CA 2101775C
Authority
CA
Canada
Prior art keywords
inositol
chiro
blood sugar
elevated blood
levels
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA002101775A
Other languages
English (en)
Other versions
CA2101775A1 (fr
Inventor
Joseph Larner
Alison Kennington
Laura C. Huang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UVA Licensing and Ventures Group
Original Assignee
University of Virginia Patent Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Virginia Patent Foundation filed Critical University of Virginia Patent Foundation
Publication of CA2101775A1 publication Critical patent/CA2101775A1/fr
Application granted granted Critical
Publication of CA2101775C publication Critical patent/CA2101775C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

Méthode de traitement d'un ensemble de maladies associées à des taux de glycémie élevés, prévoyant l'administration de suppléments alimentaires de chiro-inositol. Le chiro-inositol est un élément essentiel à la synthèse d'un médiateur dépendant de l'insuline qui est apparemment responsable de l'activation de la pyruvate-déshydrogénase-phosphatase. Les affections couramment associées à la résistance à l'insuline, comme l'hypertension, l'acidose lactique, l'obésité, les coronaropathies, etc. sont traitées par l'administration d'une quantité de chiro-inositol suffisante pour répondre aux besoins métaboliques.
CA002101775A 1991-01-23 1991-09-04 Methode pour abaisser l'hyperglycemie chez l'homme Expired - Fee Related CA2101775C (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64463991A 1991-01-23 1991-01-23
US644,639 1991-01-23

Publications (2)

Publication Number Publication Date
CA2101775A1 CA2101775A1 (fr) 1992-07-24
CA2101775C true CA2101775C (fr) 1998-09-29

Family

ID=24585768

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002101775A Expired - Fee Related CA2101775C (fr) 1991-01-23 1991-09-04 Methode pour abaisser l'hyperglycemie chez l'homme

Country Status (5)

Country Link
EP (1) EP0568545A4 (fr)
JP (1) JPH06504278A (fr)
AU (1) AU662720B2 (fr)
CA (1) CA2101775C (fr)
WO (1) WO1992012706A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5550166A (en) * 1995-03-17 1996-08-27 Ostlund; Richard E. Pinitol and derivatives thereof for the treatment of metabolic disorders
US20010039297A1 (en) * 1998-05-19 2001-11-08 Insmed Pharmaceuticals, Inc. Compositions and method for improving insulin sensivity and glucose metabolism in individuals with impaired fasting glucose or impaired glucose tolerance
AU5277000A (en) 1999-05-20 2000-12-12 Humanetics Corporation Stimulating transport of glucose into animal tissue by the administration of pinitol
WO2001077339A1 (fr) * 2000-04-07 2001-10-18 Merck Patent Gmbh Phosphatase deshydrogenese pyruvate humaine
JP4623996B2 (ja) * 2004-04-21 2011-02-02 株式会社スリービー たもぎ茸抽出物を有効成分とする血圧降下剤
WO2013016741A1 (fr) * 2011-07-22 2013-01-31 Smith Conrad Anton Complément alimentaire utilisable dans le cadre d'un programme d'amaigrissement

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2047686C (fr) * 1989-03-08 2000-09-05 Joseph Larner Supplement alimentaire pour les diabetiques insulinoresistants
JPH04138126A (ja) * 1990-09-29 1992-05-12 Tookai:Kk 靴拭いマット

Also Published As

Publication number Publication date
EP0568545A1 (fr) 1993-11-10
CA2101775A1 (fr) 1992-07-24
EP0568545A4 (en) 1993-11-24
WO1992012706A1 (fr) 1992-08-06
AU9056691A (en) 1992-08-27
AU662720B2 (en) 1995-09-14
JPH06504278A (ja) 1994-05-19

Similar Documents

Publication Publication Date Title
US5428066A (en) Method of reducing elevated blood sugar in humans
CA2047686C (fr) Supplement alimentaire pour les diabetiques insulinoresistants
AU689381B2 (en) Pinitol and derivatives thereof for the treatment of metabolic disorders
US5023248A (en) Method of treating diabetes with inositol triphosphate
AU2009200897B2 (en) Oils enriched with diacylglycerols and phytosterol ester for use in the reduction of cholesterol and triglycerides
EP0818196B1 (fr) Capsule, contenant un dioxabicyclo(3.3.0)octane
EP3657963A1 (fr) Composition utilisée dans le traitement prophylactique et thérapeutique de troubles de l'appareil cardiovasculaire
CA2101775C (fr) Methode pour abaisser l'hyperglycemie chez l'homme
Nordmann et al. Vitamin E disturbances during alcohol intoxication
Mortensen et al. Lactulose detoxifies in vitro short-chain fatty acid production in colonic contents induced by blood: implications for hepatic coma
Bank et al. Galactose feeding causes glomerular hyperperfusion: prevention by aldose reductase inhibition
Arbid et al. Effects of intraperitoneally injected vicine and convicine on the rat: Induction of favism‐like signs
US7834058B2 (en) Method of using catalpic acid to treat hyperinsulinemia
ALFIN-SLATER et al. Vitamin E and lipid metabolism
Wostmann et al. The cholesterol-lowering effect of commercial diet fed to germfree and conventional rats
Winston et al. Effects of chronic ethanol ingestion on liver glycogen phosphorylase in male and female rats
JPH0776522A (ja) 血糖上昇抑制剤および脂質代謝改善剤
Hämäläinen et al. Metabolism of perorally administered xylitol in rat tissues
JPH1045614A (ja) 血液凝固を阻害する食事療法食品及び医薬
KR20090066858A (ko) 당뇨병 예방 또는 치료용 약학적 조성물
KR20100111770A (ko) 혈당 및 지질 강하용 조성물
Marks Thiamine: Vitamin B1 Aneurine
FR2805164A1 (fr) Medicaments contre l'atherosclerose a base de composes derives de chromone
JP2008195719A (ja) 血糖値上昇抑制剤
BE629983A (fr)

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed